Literature DB >> 33819849

Local excision and chemoradiation for clinical node-negative anal adenocarcinoma.

Praveen D Chatani1, Dana A Dominguez1, John G Aversa1, Jeremy L Davis1, Jonathan M Hernandez1, Lily L Lai2, Andrew M Blakely3.   

Abstract

BACKGROUND: Given the lack of consensus in the surgical treatment of anal adenocarcinoma, practice-patterns demonstrate utilization of organ-preserving techniques. The adequacy of local excision compared to abdominoperineal resection (APR) as a surgical approach for stage II disease is unknown. Our study examines the utilization of local excision in the treatment of stage II anal adenocarcinoma, rates of R0 resection, and differences in overall survival compared to APR.
MATERIALS AND METHODS: Using the National Cancer Database (2004-2016), we retrospectively analyzed patients diagnosed with clinical stage II anal adenocarcinoma who received chemoradiation and surgery. Patient cohorts were assigned based on the surgical procedure they received. Propensity score matching was used to offset selection bias and confounding factors. Treatment approach, pathologic margin status, and overall survival were assessed.
RESULTS: Overall, 359 patients underwent resection of clinical stage II anal adenocarcinoma and received chemoradiation therapy. Of these patients, 87 (24%) underwent local excision, whereas 272 (76%) received an abdominoperineal resection. In a propensity score-matched cohort, patients who underwent local excision were less likely to achieve an R0 resection (40% vs 90%), and more likely to receive adjuvant instead of neoadjuvant chemoradiation. Overall survival was not significantly different between the propensity-matched groups. Surgical approach and pathologic margin status were not independently associated with overall survival.
CONCLUSIONS: Among patients with clinical stage II anal adenocarcinoma who received chemotherapy and radiation, complete resection was significantly less likely with local excision compared to abdominoperineal resection, however, overall survival was not affected. Prospective studies of neoadjuvant chemoradiation followed by local excision are warranted. Published by Elsevier Ltd.

Entities:  

Keywords:  Abdominoperineal resection; Anal cancer; Colorectal cancer; Local control; Trans-anal excision

Mesh:

Year:  2021        PMID: 33819849      PMCID: PMC8217139          DOI: 10.1016/j.suronc.2021.101551

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   2.388


  22 in total

1.  Local excision for T1 rectal tumours: are we getting better?

Authors:  C Atallah; J P Taylor; B D Lo; M Stem; T Brocke; J E Efron; B Safar
Journal:  Colorectal Dis       Date:  2020-10-20       Impact factor: 3.788

2.  Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma.

Authors:  Richard Li; Ashwin Shinde; Marwan Fakih; Stephen Sentovich; Kurt Melstrom; Rebecca Nelson; Scott Glaser; Yi-Jen Chen; Karyn Goodman; Arya Amini
Journal:  J Natl Compr Canc Netw       Date:  2019-10-01       Impact factor: 11.908

3.  Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database.

Authors:  Ravi P Kiran; Matteo Rottoli; Naveen Pokala; Victor W Fazio
Journal:  Dis Colon Rectum       Date:  2010-04       Impact factor: 4.585

4.  Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.

Authors:  Oliver K Jawitz; Mohamed A Adam; Megan C Turner; Brian F Gilmore; John Migaly
Journal:  Surgery       Date:  2019-03-21       Impact factor: 3.982

5.  Surgical therapy for anorectal melanoma.

Authors:  Kelli M Bullard; Todd M Tuttle; David A Rothenberger; Robert D Madoff; Nancy N Baxter; Charles O Finne; Michael P Spencer
Journal:  J Am Coll Surg       Date:  2003-02       Impact factor: 6.113

6.  Locoregional lymphadenectomy in the surgical management of anorectal melanoma.

Authors:  Daniel R Perez; Atthaphorn Trakarnsanga; Jinru Shia; Garrett M Nash; Larissa K Temple; Philip B Paty; Jose G Guillem; Julio Garcia-Aguilar; Danielle Bello; Charlotte Ariyan; Richard D Carvajal; Martin R Weiser
Journal:  Ann Surg Oncol       Date:  2013-01-18       Impact factor: 5.344

7.  Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network.

Authors:  Yazid Belkacémi; Christine Berger; Philip Poortmans; Gaëlle Piel; Abderrahim Zouhair; Jean-Baptiste Méric; Tan-Dat Nguyen; Marco Krengli; Franck Behrensmeier; Abdelkarim Allal; Dany De Looze; Jacques Bernier; Luciano Scandolaro; René-Olivier Mirimanoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

8.  Primary adenocarcinoma of the anus treated with combined modality therapy.

Authors:  Kathryn P Beal; Douglas Wong; Jose G Guillem; Philip B Paty; Leonard L Saltz; Raquel Wagman; Bruce D Minsky
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

9.  Quality of life in patients treated for anal carcinoma-a systematic literature review.

Authors:  Anton Sterner; Kristoffer Derwinger; Caroline Staff; Hanna Nilsson; Eva Angenete
Journal:  Int J Colorectal Dis       Date:  2019-07-19       Impact factor: 2.571

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  1 in total

Review 1.  Management and Outcomes in Anal Canal Adenocarcinomas-A Systematic Review.

Authors:  Vasilis Taliadoros; Henna Rafique; Shahnawaz Rasheed; Paris Tekkis; Christos Kontovounisios
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.